The head of the Food and Drug Administration’s drug center abruptly resigned Sunday amid concerns about his personal conduct.
U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...
Fresenius Kabi has received the Food and Drug Administration’s permission for Conexxence (denosumab-bnht) and Bomyntra ...
Dozens of scientists are considering leaving the Center for Biologics Evaluation and Research, where Prasad serves as ...
Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...
During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
Zacks Investment Research on MSN
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers Squibb Company BMY reported third-quarter 2025 adjusted earnings per share (EPS) of $1.63, which comfortably ...
Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback